Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

This page contains information on reimbursement for ILARIS® (canakinumab) treatment for the following autoinflammatory periodic fever syndrome (PFS): familial Mediterranean fever (FMF), hyperimmunoglobulin D syndrome (HIDS)/ mevalonate kinase deficiency (MKD) and tumour necrosis factor receptor-associated periodic syndrome (TRAPS) in adults, adolescents and children aged ≥2 years.1

NHS England has confirmed that there is sufficient evidence to support a policy for the routine commissioning of ILARIS in the periodic fever syndromes: TRAPS, HIDS/MKD and FMF, providing funding for an estimated 134 patients
with PFS
in England1-3

 

NHS England commissioning

Centres with expertise in adult rheumatology, or adult/paediatric immunology (as appropriate), may prescribe this treatment after discussion with an NHS trust based in England:1

  • Treatment with ILARIS should be managed within specialist centres that have the expertise to manage these complex conditions1
  • These centres are members of the Rare Immunodeficiency, Autoinflammatory and Autoimmune Disease Network (RITA) European Research Network (ERN)1

To find out more about commissioning of ILARIS, click here.

 

Could your patient be the 1 in 134?2,3

ilaris eligible patient icon

Find out if your patient is eligible for treatment with ILARIS on our patient identification page.

 

If your patient(s) is eligible for treatment with ILARIS, contact your nearest RITA-ERN centre.4 Use the interactive map below to find your nearest centre’s contact details and expertise:

For a full list of RITA-ERN centres and their contact details, click here.

 

ilaris money icon

For help completing an individual funding request (IFR), contact us.

 

ilaris homecare icon

Adult and paediatric patients who have been prescribed ILARIS are eligible for ILARIS Homecare. View more information about how ILARIS Homecare can support you and your patients.

*Due to Brexit, HCPs from the UK are formally not ERN-HCP any more; however, to enable ongoing collaboration these centres are regarded as collaborative partners.4

Indications5
Periodic fever syndromes
ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

  • CAPS, including:
    • Muckle-Wells syndrome (MWS)
    • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
    • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash
  • TRAPS
  • HIDS/MKD
  • FMF 
    • ILARIS should be given in combination with colchicine, if appropriate

Still’s disease
ILARIS is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. ILARIS can be given as monotherapy or in combination with methotrexate.

AI, autoimmune disease; AID, autoinflammatory disorder; AOSD, adult-onset Still’s disease; CAPS, cryopyrin-associated periodic syndrome; CINCA, chronic infantile neurological, cutaneous, articular syndrome; ERN, European Research Network; FCAS, severe forms of familial cold autoinflammatory syndrome; FCU, familial cold urticaria; FMF, familial Mediterranean fever; HCP, healthcare professional; HIDS, hyperimmunoglobulin D syndrome; IFR, individual funding request; MKD, mevalonate kinase deficiency; MWS, Muckle-Wells syndrome; NHS, National Health Service; NOMID, neonatal-onset multisystem inflammatory disease; NSAID, non-steroidal anti-inflammatory drug; PFS, periodic fever syndrome; PID, primary immunodeficiency; PR, paediatric rheumatic disease; RITA, Rare Immunodeficiency, Autoinflammatory and Autoimmune Disease Network; SJIA, systemic juvenile idiopathic arthritis; TRAPS, tumour necrosis factor receptor-associated periodic syndrome.

References

  1. National Health Service England. Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older). Available at: https://www.england.nhs.uk/publication/canakinumab-for-treating-periodic... [Accessed May 2023]. 
  2. National Health Executive. NHS England approved funding for drug to help rare conditions. Available at: https://www.nationalhealthexecutive.com/News/nhs-england-drug-pfs [Accessed May 2023].
  3. NHS. Live changing fever, headache and painkilling drug for children on the NHS. Available at: https://www.england.nhs.uk/2020/02/life-changing-fever-headache-and-pain... [Accessed May 2023].
  4. RITA-ERN. Reference centres. Available at: https://ern-rita.org/hcps [Accessed May 2023].
  5. ILARIS® (canakinumab) Summary of Product Characteristics.
Rate this content: 
Average: 4 (1 vote)
UK | May 2023 | 261186

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]